source
- 92Bio revives experimental T cell engager previously handed to Amgen92Bio, a small California biotech, announced it is bringing back an experimental T‑cell engager it originally created before transferring the program to Amgen. The company said the candidate will…
- Sanofi’s Pompe disease enzyme therapy clears Phase 3 in infants, opening US label expansionSanofi announced that its next‑generation enzyme replacement therapy for Pompe disease met its primary endpoints in a registrational Phase 3 trial involving infants with the severe infantile‑onset…